BioNTech SE (F:22UAy) (NASDAQ:BNTX) has been downgraded to “market perform” from “outperform” by Leerink Partners after a ...

After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.

To help answer common vaccine questions, we consulted Dr. Stanley Perlman, a professor at the University of Iowa’s Carver ...

BioNTech (NasdaqGS:BNTX) has appointed Kylie Jimenez as Chief People Officer. The new executive role is designed to support BioNTech's goal of becoming a multi product oncology company by 2030. This ...

BioNTech (NasdaqGS:BNTX) shares came under pressure after Leerink Partners downgraded the stock, citing limited near term upside from cancer vaccine data, particularly after a recent 24% rally. See ...

German biotech BioNTech today announced that the US Food and Drug Administration (FDA) has granted fast track designation to ...

The downgrade follows a 24% rise in BioNTech’s shares to $113 from December lows of $92, a move that outpaced the 4% gain in the S&P Biotechnology Select Industry Index over the same period. Leerink ...

Kylie Jimenez is a seasoned global HR executive with more than 20 years of experience in shaping and scaling international organizations. She will join BioNTech from the international manufacturing ...

We came across a bullish thesis on BioNTech SE on Lux Opes Research’s Substack. In this article, we will summarize the bulls’ ...

U.S.-based pharmaceutical giant German biotech company BioNTech were already collaborating to come up with a flu vaccine ...

BioNTech SE is methodically advancing its transition from a COVID-19 vaccine specialist to a fully-fledged oncology company, achieving significant regulatory and operational milestones in early 2026.

A key asset in this strategy, BNT113, recently achieved a critical regulatory milestone. On January 21, 2026, the U.S. Food and Drug Administration (FDA) granted "Fast Track" designation to this ...